- Home
- STKS vs SNTI Comparison
STKS vs SNTI Comparison
Compare STKS & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- SNTI
- Stock Information
- Founded
- STKS 2004
- SNTI 2016
- Country
- STKS United States
- SNTI United States
- Employees
- STKS N/A
- SNTI N/A
- Industry
- STKS Restaurants
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- STKS Consumer Discretionary
- SNTI Health Care
- Exchange
- STKS Nasdaq
- SNTI Nasdaq
- Market Cap
- STKS 112.2M
- SNTI 85.3M
- IPO Year
- STKS N/A
- SNTI N/A
- Fundamental
- Price
- STKS $3.44
- SNTI $3.14
- Analyst Decision
- STKS Buy
- SNTI Strong Buy
- Analyst Count
- STKS 2
- SNTI 1
- Target Price
- STKS $4.25
- SNTI $12.00
- AVG Volume (30 Days)
- STKS 64.0K
- SNTI 27.9K
- Earning Date
- STKS 05-07-2025
- SNTI 05-06-2025
- Dividend Yield
- STKS N/A
- SNTI N/A
- EPS Growth
- STKS N/A
- SNTI N/A
- EPS
- STKS N/A
- SNTI N/A
- Revenue
- STKS $799,478,000.00
- SNTI N/A
- Revenue This Year
- STKS $28.11
- SNTI N/A
- Revenue Next Year
- STKS $5.26
- SNTI N/A
- P/E Ratio
- STKS N/A
- SNTI N/A
- Revenue Growth
- STKS 138.50
- SNTI N/A
- 52 Week Low
- STKS $2.37
- SNTI $1.52
- 52 Week High
- STKS $5.42
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- STKS 47.38
- SNTI 44.57
- Support Level
- STKS $3.33
- SNTI $3.03
- Resistance Level
- STKS $3.93
- SNTI $3.50
- Average True Range (ATR)
- STKS 0.31
- SNTI 0.22
- MACD
- STKS -0.09
- SNTI 0.00
- Stochastic Oscillator
- STKS 8.38
- SNTI 23.40
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.